Combined Use of Interferon Alpha-2b Drugs with Tetravalent Vaccine against Reinfection in HPV Female Patients

Introduction: The most widespread viral infection of the urogenital tract, papillomavirus infection is the cause of precancerous lesions and HPV-related cancers of various sites. Although in young women, the majority of lesions caused by HPV cause no symptoms and improve spontaneously, the permanent presence of HPV in the organism can lead to an oncological disease developing. With regard to this, the possibility of human papillomavirus reinfection throughout life and the presence of multiple HPV types in one female patient, which inevitably increases the risk of HPV-associated precancerous diseases developing in young women, too, are especially relevant. Objective of the research: optimization of the management tactics of HPV-positive young women by using interferon alpha and tetravalent vaccine. Materials and methods: The research involved female patients aged 16 to 25 infected with human papillomavirus. The groups under comparison underwent observation, vaccination with tetravalent vaccine, and the use of interferon alpha-2b combined with vaccination. Results and conclusion: The research has shown that the management tactics of HPV-positive young women including the use of interferon alpha and tetravalent vaccine helps increase the extent of elimination of the virus and prevents relapses of the viral infection and HPV-associated diseases as compared to female patients from the comparison groups.